<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379169</url>
  </required_header>
  <id_info>
    <org_study_id>SBEYE</org_study_id>
    <nct_id>NCT02379169</nct_id>
  </id_info>
  <brief_title>Effects of Sea Buckthorn Oil and Lutein on Eye Health</brief_title>
  <acronym>SBEYE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aromtech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low macular pigment optical density has been associated with increased risk of age-related
      macular degeneration, an important cause of vision problems in the elderly population. Dry
      eye is multifactorial disease of tears and the ocular surface associated with symptoms of
      dryness, grittiness, burning and redness of eyes. The risk of dry eye increases with age. The
      aim is to investigate the effects of sea buckthorn oil complemented with lutein on eye
      health, specifically on the macula.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in macular pigment optical density from baseline to 6 mo</measure>
    <time_frame>0 mo, 3 mo, 6 mo</time_frame>
    <description>measurement of macular pigment optical density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of dry eye from baseline to 6 mo</measure>
    <time_frame>0 months, 3 months, 6 months</time_frame>
    <description>questionnaires, symptom logbook</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipids (Triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol) from baseline to 6 mo</measure>
    <time_frame>0 months, 6 months</time_frame>
    <description>analysis from serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum markers of inflammation (hs-CRP) from baseline to 6 mo</measure>
    <time_frame>0 months, 6 months</time_frame>
    <description>analysis from serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating aminotransferases (ALAT, ASAT) from baseline to 6 mo</measure>
    <time_frame>0 months, 6 months</time_frame>
    <description>analysis from plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in contrast sensitivity from baseline to 6 mo</measure>
    <time_frame>0 mo, 3 mo, 6 mo</time_frame>
    <description>analysis of contrast sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vision aquity from baseline to 6 mo</measure>
    <time_frame>0 mo, 3 mo, 6 mo</time_frame>
    <description>ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vision functioning from baseline to 6 mo</measure>
    <time_frame>0 mo, 3 mo, 6 mo</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tear film osmolarity from baseline to 6 mo</measure>
    <time_frame>0 mo, 3 mo, 6 mo</time_frame>
    <description>measurement of tear film osmolarity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum markers of sea buckthorn oil and lutein intake</measure>
    <time_frame>0 months, 6 months</time_frame>
    <description>analysis from serum samples</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Risk Factors for Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sea buckthorn &amp; lutein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sea buckthorn oil &amp; lutein</intervention_name>
    <description>Standardised sea buckthorn seed and pulp oil complemented with lutein</description>
    <arm_group_label>Sea buckthorn &amp; lutein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Triglycerides of medium chain fatty acids</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - macular pigment optical density equal to or less than 0,40 OD

        Exclusion Criteria:

          -  diabetic retinopathy

          -  macular changes associated with high blood pressure

          -  signs of macular degeneration: classes 2, 3 and 4 according to the Rotterdam study
             (Mol Vis 2012: 657-74)

          -  severe eye diseases, exluding cataract. The intervention will begina after surgery and
             recovery from cataract
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macular pigment optical density, age related macular degeneration, dry eye, vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

